97 related articles for article (PubMed ID: 32638009)
21. Prognostic meta-signature of breast cancer developed by two-stage mixture modeling of microarray data.
Shen R; Ghosh D; Chinnaiyan AM
BMC Genomics; 2004 Dec; 5(1):94. PubMed ID: 15598354
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value.
Lehmann BD; Ding Y; Viox DJ; Jiang M; Zheng Y; Liao W; Chen X; Xiang W; Yi Y
BMC Cancer; 2015 Mar; 15():179. PubMed ID: 25886164
[TBL] [Abstract][Full Text] [Related]
23. GSMA: an approach to identify robust global and test Gene Signatures using Meta-Analysis.
Shafi A; Nguyen T; Peyvandipour A; Draghici S
Bioinformatics; 2020 Jan; 36(2):487-495. PubMed ID: 31329248
[TBL] [Abstract][Full Text] [Related]
24. Robust clustering of noisy high-dimensional gene expression data for patients subtyping.
Coretto P; Serra A; Tagliaferri R
Bioinformatics; 2018 Dec; 34(23):4064-4072. PubMed ID: 29939219
[TBL] [Abstract][Full Text] [Related]
25. Asynchronous and pathological windows of implantation: two causes of recurrent implantation failure.
Sebastian-Leon P; Garrido N; Remohí J; Pellicer A; Diaz-Gimeno P
Hum Reprod; 2018 Apr; 33(4):626-635. PubMed ID: 29452422
[TBL] [Abstract][Full Text] [Related]
26. Absolute assignment of breast cancer intrinsic molecular subtype.
Paquet ER; Hallett MT
J Natl Cancer Inst; 2015 Jan; 107(1):357. PubMed ID: 25479802
[TBL] [Abstract][Full Text] [Related]
27. Stable gene expression for normalisation and single-sample scoring.
Bhuva DD; Cursons J; Davis MJ
Nucleic Acids Res; 2020 Nov; 48(19):e113. PubMed ID: 32997146
[TBL] [Abstract][Full Text] [Related]
28. Consensus of gene expression phenotypes and prognostic risk predictors in primary lung adenocarcinoma.
Ringnér M; Staaf J
Oncotarget; 2016 Aug; 7(33):52957-52973. PubMed ID: 27437773
[TBL] [Abstract][Full Text] [Related]
29. Building trans-omics evidence: using imaging and 'omics' to characterize cancer profiles.
Srivastava A; Kulkarni C; Mallick P; Huang K; Machiraju R
Pac Symp Biocomput; 2018; 23():377-387. PubMed ID: 29218898
[TBL] [Abstract][Full Text] [Related]
30. Platform-Independent Classification System to Predict Molecular Subtypes of High-Grade Serous Ovarian Carcinoma.
Shilpi A; Kandpal M; Ji Y; Seagle BL; Shahabi S; Davuluri RV
JCO Clin Cancer Inform; 2019 Apr; 3():1-9. PubMed ID: 31002564
[TBL] [Abstract][Full Text] [Related]
31. Transcriptomic and Protein Expression Analysis Reveals Clinicopathological Significance of Bloom Syndrome Helicase (BLM) in Breast Cancer.
Arora A; Abdel-Fatah TM; Agarwal D; Doherty R; Moseley PM; Aleskandarany MA; Green AR; Ball G; Alshareeda AT; Rakha EA; Chan SY; Ellis IO; Madhusudan S
Mol Cancer Ther; 2015 Apr; 14(4):1057-65. PubMed ID: 25673821
[TBL] [Abstract][Full Text] [Related]
32. E2F4 regulatory program predicts patient survival prognosis in breast cancer.
Khaleel SS; Andrews EH; Ung M; DiRenzo J; Cheng C
Breast Cancer Res; 2014 Dec; 16(6):486. PubMed ID: 25440089
[TBL] [Abstract][Full Text] [Related]
33. Proteomic analysis of breast tumors confirms the mRNA intrinsic molecular subtypes using different classifiers: a large-scale analysis of fresh frozen tissue samples.
Waldemarson S; Kurbasic E; Krogh M; Cifani P; Berggård T; Borg Å; James P
Breast Cancer Res; 2016 Jun; 18(1):69. PubMed ID: 27357824
[TBL] [Abstract][Full Text] [Related]
34. Analysis of genomic and transcriptomic variations as prognostic signature for lung adenocarcinoma.
Zengin T; Önal-Süzek T
BMC Bioinformatics; 2020 Sep; 21(Suppl 14):368. PubMed ID: 32998690
[TBL] [Abstract][Full Text] [Related]
35. Prognostic value of transcriptomic determination of tumour-infiltrating lymphocytes in localised breast cancer.
Truntzer C; Isambert N; Arnould L; Ladoire S; Ghiringhelli F
Eur J Cancer; 2019 Oct; 120():97-106. PubMed ID: 31499385
[TBL] [Abstract][Full Text] [Related]
36. Research-based PAM50 signature and long-term breast cancer survival.
Pu M; Messer K; Davies SR; Vickery TL; Pittman E; Parker BA; Ellis MJ; Flatt SW; Marinac CR; Nelson SH; Mardis ER; Pierce JP; Natarajan L
Breast Cancer Res Treat; 2020 Jan; 179(1):197-206. PubMed ID: 31542876
[TBL] [Abstract][Full Text] [Related]
37. Simultaneous discovery of cancer subtypes and subtype features by molecular data integration.
Le Van T; van Leeuwen M; Carolina Fierro A; De Maeyer D; Van den Eynden J; Verbeke L; De Raedt L; Marchal K; Nijssen S
Bioinformatics; 2016 Sep; 32(17):i445-i454. PubMed ID: 27587661
[TBL] [Abstract][Full Text] [Related]
38. A novel non-parametric method for uncertainty evaluation of correlation-based molecular signatures: its application on PAM50 algorithm.
Fresno C; González GA; Merino GA; Flesia AG; Podhajcer OL; Llera AS; Fernández EA
Bioinformatics; 2017 Mar; 33(5):693-700. PubMed ID: 28062443
[TBL] [Abstract][Full Text] [Related]
39. Prognostic stromal gene signatures in breast cancer.
Winslow S; Leandersson K; Edsjö A; Larsson C
Breast Cancer Res; 2015 Feb; 17(1):23. PubMed ID: 25848820
[TBL] [Abstract][Full Text] [Related]
40. MINT: a multivariate integrative method to identify reproducible molecular signatures across independent experiments and platforms.
Rohart F; Eslami A; Matigian N; Bougeard S; Lê Cao KA
BMC Bioinformatics; 2017 Feb; 18(1):128. PubMed ID: 28241739
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
